Senior Correspondent, London
Ben's Feed
Aug 24, 2014

Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON/ZURICH, Aug 24 (Reuters) – Roche Holding AG
has agreed to buy U.S. biotech company InterMune Inc
for $8.3 billion in cash, marking the latest multibillion-dollar
deal in a consolidating pharmaceutical sector.

The Swiss drugmaker said on Sunday it would pay $74.00 a
share for InterMune, representing a premium of 38 percent to the
closing price on Aug. 22.

Aug 22, 2014
Aug 21, 2014
Aug 21, 2014
Aug 21, 2014

Pfizer back for AstraZeneca? Year-end move seen most likely

LONDON (Reuters) – Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt in May.

But while British takeover rules mean deal talks could be back on the cards as early as Aug. 26, following the ending of the first of a two-stage cooling-off period, many investors and analysts see the year-end as a more likely time for any return.

Aug 21, 2014
Aug 20, 2014
Aug 20, 2014
Aug 20, 2014

Our life with the Neanderthals was no brief affair

LONDON (Reuters) – Far from wiping out Neanderthals overnight, modern humans rubbed along with their shorter and stockier cousins for thousands of years, giving plenty of time for the two groups to share ideas – and have sex.

The most accurate timeline yet for the demise of our closest relatives, published on Wednesday, shows Neanderthals overlapped with present-day humans in Europe for between 2,600 and 5,400 years before disappearing about 40,000 years ago.

Aug 20, 2014

Experimental Ebola drugs needed for ‘up to 30,000 people’

LONDON (Reuters) – Up to 30,000 people could have used experimental treatments or vaccines so far in the world’s worst outbreak of Ebola currently plaguing West Africa, British scientists said on Wednesday.

The calculation highlights the dilemma facing officials considering how to distribute the tiny quantities of unproven drugs that are likely to be available in the near term to fight the deadly disease.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben